Q3 Earnings Estimate for RMTI Issued By Maxim Group

Rockwell Medical, Inc. (NASDAQ:RMTI) – Analysts at Maxim Group issued their Q3 2026 EPS estimates for Rockwell Medical in a research report issued to clients and investors on Tuesday, November 10th. Maxim Group analyst A. Vendetti anticipates that the company will post earnings of ($0.23) per share for the quarter. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.90) per share.

Rockwell Medical (NASDAQ:RMTI) last posted its earnings results on Thursday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. The company had revenue of $19.12 million during the quarter, compared to analysts’ expectations of $18.22 million. Rockwell Medical had a negative net margin of 7.33% and a negative return on equity of 14.03%.

A number of other equities research analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Rockwell Medical in a report on Friday, September 11th. Wall Street Zen upgraded Rockwell Medical to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings raised Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. Finally, Zacks Research cut Rockwell Medical from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $20.00.

Rockwell Medical Price Performance

Rockwell Medical stock opened at $7.08 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.25 and a quick ratio of 3.00. Rockwell Medical has a twelve month low of $4.89 and a twelve month high of $12.90. The company’s 50-day moving average price is $7.83 and its two-hundred day moving average price is $8.11.

Institutional Trading of Rockwell Medical

A hedge fund recently bought a new position in Rockwell Medical stock. Corsair Capital Management L.P. purchased a new position in Rockwell Medical, Inc. (NASDAQ:RMTI) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $45,000. Corsair Capital Management L.P. owned 0.13% of Rockwell Medical as of its most recent filing with the Securities and Exchange Commission (SEC). 23.31% of the stock is currently owned by hedge funds and other institutional investors.

About Rockwell Medical

Rockwell Medical, Inc. is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care. Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.